Do analysts rate NCEL or APLM?

NLS Pharmaceutics currently has a consensus target price of $23.00, indicating a potential upside of 707.02%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, research analysts plainly believe NLS Pharmaceutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, NCEL or APLM?

NLS Pharmaceutics has higher earnings, but lower revenue than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Apollomics $8.50M 8.10 -$10.94M N/A N/A

Is NCEL or APLM more profitable?

Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Apollomics N/A N/A N/A

Which has higher valuation & earnings, NCEL or RNTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A

Is NCEL or RNTX more profitable?

Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Rein Therapeutics N/A N/A -63.69%

Does the media favor NCEL or RNTX?

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 2 articles in the media. Rein Therapeutics' average media sentiment score of 1.20 beat NLS Pharmaceutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rein Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NCEL or KLRS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A

Is NCEL or KLRS more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Kalaris Therapeutics N/A -71.71% -42.95%

Does the media favor NCEL or KLRS?

In the previous week, NLS Pharmaceutics had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for NLS Pharmaceutics and 1 mentions for Kalaris Therapeutics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Kalaris Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, NCEL or OKYO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is NCEL or OKYO more profitable?

Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A OKYO Pharma N/A N/A N/A

Does the media prefer NCEL or OKYO?

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 2 articles in the media. NLS Pharmaceutics' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OKYO Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer XBIT or NCEL?

NLS Pharmaceutics has a consensus price target of $23.00, indicating a potential upside of 707.02%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, analysts plainly believe NLS Pharmaceutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, XBIT or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.48 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is XBIT or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat XBiotech's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -31.62% -30.29% NLS Pharmaceutics N/A N/A N/A

Does the media refer more to XBIT or NCEL?

In the previous week, NLS Pharmaceutics had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for NLS Pharmaceutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 0.75 beat NLS Pharmaceutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NLS Pharmaceutics (NCEL) Competitors

$2.85 -0.06 (-2.06%)

As of 10/2/2026 01:41 PM Eastern

Compare

NCEL vs. APLM, RNTX, KLRS, OKYO, and XBIT

Should you buy NLS Pharmaceutics stock or one of its competitors? NLS Pharmaceutics's main competitors and comparable companies include Apollomics (APLM), Rein Therapeutics (RNTX), Kalaris Therapeutics (KLRS), OKYO Pharma (OKYO), and XBiotech (XBIT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NLS Pharmaceutics compare to Apollomics?

NLS Pharmaceutics (NASDAQ:NCEL) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

NLS Pharmaceutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

NLS Pharmaceutics has higher earnings, but lower revenue than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Apollomics	$8.50M	8.10	-$10.94M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Apollomics	N/A	N/A	N/A

NLS Pharmaceutics currently has a consensus target price of $23.00, indicating a potential upside of 707.02%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, research analysts plainly believe NLS Pharmaceutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, NLS Pharmaceutics had 2 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for NLS Pharmaceutics and 0 mentions for Apollomics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Apollomics	Neutral

19.1% of Apollomics shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

NLS Pharmaceutics beats Apollomics on 6 of the 9 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Rein Therapeutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

NLS Pharmaceutics currently has a consensus target price of $23.00, indicating a potential upside of 707.02%. Rein Therapeutics has a consensus target price of $6.00, indicating a potential upside of 649.34%. Given NLS Pharmaceutics' higher probable upside, research analysts plainly believe NLS Pharmaceutics is more favorable than Rein Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

90.9% of Rein Therapeutics shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NLS Pharmaceutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Rein Therapeutics	N/A	N/A	-63.69%

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 2 articles in the media. Rein Therapeutics' average media sentiment score of 1.20 beat NLS Pharmaceutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rein Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rein Therapeutics beats NLS Pharmaceutics on 5 of the 9 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Kalaris Therapeutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

NLS Pharmaceutics has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

66.1% of Kalaris Therapeutics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NLS Pharmaceutics' return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Kalaris Therapeutics	N/A	-71.71%	-42.95%

NLS Pharmaceutics presently has a consensus target price of $23.00, suggesting a potential upside of 707.02%. Kalaris Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 594.44%. Given NLS Pharmaceutics' higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, NLS Pharmaceutics had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for NLS Pharmaceutics and 1 mentions for Kalaris Therapeutics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Kalaris Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

Summary

NLS Pharmaceutics beats Kalaris Therapeutics on 6 of the 10 factors compared between the two stocks.

How does NLS Pharmaceutics compare to OKYO Pharma?

NLS Pharmaceutics (NASDAQ:NCEL) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

NLS Pharmaceutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market.

NLS Pharmaceutics currently has a consensus target price of $23.00, indicating a potential upside of 707.02%. OKYO Pharma has a consensus target price of $5.67, indicating a potential upside of 285.49%. Given NLS Pharmaceutics' higher probable upside, research analysts plainly believe NLS Pharmaceutics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
OKYO Pharma	N/A	N/A	N/A

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 2 articles in the media. NLS Pharmaceutics' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OKYO Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.0% of OKYO Pharma shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

OKYO Pharma beats NLS Pharmaceutics on 4 of the 7 factors compared between the two stocks.

How does NLS Pharmaceutics compare to XBiotech?

XBiotech (NASDAQ:XBIT) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

NLS Pharmaceutics has a consensus price target of $23.00, indicating a potential upside of 707.02%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, analysts plainly believe NLS Pharmaceutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

XBiotech has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

55.7% of XBiotech shares are held by institutional investors. 30.8% of XBiotech shares are held by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NLS Pharmaceutics' return on equity of 0.00% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
NLS Pharmaceutics	N/A	N/A	N/A

In the previous week, NLS Pharmaceutics had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for NLS Pharmaceutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 0.75 beat NLS Pharmaceutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NLS Pharmaceutics beats XBiotech on 8 of the 11 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCEL vs. The Competition

Export

Metric	NLS Pharmaceutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.46M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	N/A	13.06	275.66	26.04
Price / Sales	N/A	1,295.73	609.44	91.76
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	1.79	16.63	10.93	6.31
Net Income	-$8.30M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-3.39%	-2.99%	-2.00%	-1.66%
1 Month Performance	-14.93%	-10.60%	-6.15%	-4.50%
1 Year Performance	-85.75%	19.44%	7.44%	2.06%

NLS Pharmaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCEL NLS Pharmaceutics	1.9339 of 5 stars	$2.85 -2.1%	$23.00 +707.0%	-86.6%	$16.46M	N/A	N/A	6	Positive News
APLM Apollomics	1.6164 of 5 stars	$23.95 -0.7%	N/A	+28.4%	$69.82M	$8.50M	N/A	15
RNTX Rein Therapeutics	2.837 of 5 stars	$0.82 +3.9%	$6.00 +630.8%	-31.0%	$69.79M	N/A	N/A	10	News Coverage Positive News
KLRS Kalaris Therapeutics	2.7646 of 5 stars	$2.88 -0.7%	$18.75 +551.3%	-61.9%	$68.46M	N/A	N/A	110	News Coverage
OKYO OKYO Pharma	2.1818 of 5 stars	$1.30 -4.2%	$5.67 +334.9%	-25.8%	$68.22M	N/A	N/A	5	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCEL) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. APLM, RNTX, KLRS, OKYO, and XBIT

How does NLS Pharmaceutics compare to Apollomics?

Summary

How does NLS Pharmaceutics compare to Rein Therapeutics?

Summary

How does NLS Pharmaceutics compare to Kalaris Therapeutics?

Summary

How does NLS Pharmaceutics compare to OKYO Pharma?

Summary

How does NLS Pharmaceutics compare to XBiotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. APLM, RNTX, KLRS, OKYO, and XBIT

How does NLS Pharmaceutics compare to Apollomics?

Which has more risk and volatility, NCEL or APLM?

Which has higher valuation & earnings, NCEL or APLM?

Is NCEL or APLM more profitable?

Do analysts rate NCEL or APLM?

Does the media favor NCEL or APLM?

Do insiders and institutionals have more ownership in NCEL or APLM?

Summary

How does NLS Pharmaceutics compare to Rein Therapeutics?

Do analysts rate NCEL or RNTX?

Do insiders and institutionals have more ownership in NCEL or RNTX?

Which has more risk and volatility, NCEL or RNTX?

Which has higher valuation & earnings, NCEL or RNTX?

Is NCEL or RNTX more profitable?

Does the media favor NCEL or RNTX?

Summary

How does NLS Pharmaceutics compare to Kalaris Therapeutics?

Which has more risk & volatility, NCEL or KLRS?

Do insiders and institutionals hold more shares of NCEL or KLRS?

Is NCEL or KLRS more profitable?

Do analysts prefer NCEL or KLRS?

Does the media favor NCEL or KLRS?

Which has stronger valuation and earnings, NCEL or KLRS?

Summary

How does NLS Pharmaceutics compare to OKYO Pharma?

Which has stronger earnings and valuation, NCEL or OKYO?

Which has more risk and volatility, NCEL or OKYO?

Do analysts prefer NCEL or OKYO?

Is NCEL or OKYO more profitable?

Does the media prefer NCEL or OKYO?

Do institutionals and insiders believe in NCEL or OKYO?

Summary

How does NLS Pharmaceutics compare to XBiotech?

Do analysts prefer XBIT or NCEL?

Which has preferable earnings & valuation, XBIT or NCEL?

Which has more volatility and risk, XBIT or NCEL?

Do insiders and institutionals have more ownership in XBIT or NCEL?

Is XBIT or NCEL more profitable?

Does the media refer more to XBIT or NCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools